Adaptive and Genentech Partner to Use clonoSEQ® Assay to Measure Minimal Residual Disease as a Primary Endpoint in Phase III Study of Chronic Lymphocytic Leukemia Patients

Daniel Sontupe
Market Access

Joey Cohen
Medication Adherence

Amy Giles
Increasing Engagement

Frank Burrell
Scientific Storytelling

Pat Purcell
Meeting Engagement

Suma Ramadas, PhD
Medical Affairs

Brenda Snow
Authentic Patient Voice

Paul Theisen
Patient Acquisition

Liz Kane
Impactful Strategy

David Linetsky
Point-of-Care Marketing

Matthew Durham
Omnidynamic Marketing

Stacey Gandler
Brand Nourishment

Matt Turner
Patient Affordability

Bud Bilanich
Success Coach